Search hospitals > Nevada > Las Vegas
Las Vegas Cancer Center-Medical Center
Claim this profileLas Vegas, Nevada 89106
Global Leader in Parotid Gland Cancer
Global Leader in Relapse
Conducts research for Cervical Adenocarcinoma
Conducts research for Ovarian Cancer
Conducts research for Cancer
253 reported clinical trials
5 medical researchers
Summary
Las Vegas Cancer Center-Medical Center is a medical facility located in Las Vegas, Nevada. This center is recognized for care of Parotid Gland Cancer, Relapse, Cervical Adenocarcinoma, Ovarian Cancer, Cancer and other specialties. Las Vegas Cancer Center-Medical Center is involved with conducting 253 clinical trials across 413 conditions. There are 5 research doctors associated with this hospital, such as John A. Ellerton, Alan K. Ikeda, Nicola M. Spirtos, and Peter Lim.Area of expertise
1Parotid Gland Cancer
Global LeaderStage IV
Stage III
Stage I
2Relapse
Global LeaderStage IV
Stage III
Stage I
Top PIs
John A. EllertonOptumCare Cancer Care at Fort Apache6 years of reported clinical research
Expert in Parotid Gland Cancer
Expert in Breast Cancer
158 reported clinical trials
235 drugs studied
Alan K. IkedaAlliance for Childhood Diseases/Cure 4 the Kids Foundation8 years of reported clinical research
Expert in Cancer
Expert in Adult T-Cell Leukemia/Lymphoma
55 reported clinical trials
111 drugs studied
Nicola M. SpirtosWomen's Cancer Center of Nevada1 year of reported clinical research
Expert in Parotid Gland Cancer
Expert in Cervical Adenocarcinoma
23 reported clinical trials
50 drugs studied
Peter LimCenter of Hope2 years of reported clinical research
Studies Ovarian Cancer
Studies Fallopian Tube Cancer
13 reported clinical trials
20 drugs studied
Clinical Trials running at Las Vegas Cancer Center-Medical Center
Breast Cancer
Bladder Cancer
Cancer
Lung Cancer
Parotid Gland Cancer
Endometrial Cancer
Bladder Carcinoma
Uterine Cancer
Kidney Cancer
Ovarian Cancer
Marker-Directed Monitoring
for Breast Cancer
This trial studies if using blood tests to decide when to do scans is as effective as the standard way for monitoring patients with a specific type of breast cancer that has spread. The blood tests act like an early warning system for cancer activity.
Recruiting1 award N/A
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
Questionnaire Choice
for Cancer Data Quality
The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO.
Recruiting1 award N/A11 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Las Vegas Cancer Center-Medical Center?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.